QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

$284.32
-1.98 (-0.69%)
(As of 04:37 PM ET)
Today's Range
$284.21
$288.57
50-Day Range
$268.87
$324.56
52-Week Range
$211.71
$329.72
Volume
2.28 million shs
Average Volume
3.04 million shs
Market Capitalization
$152.37 billion
P/E Ratio
22.76
Dividend Yield
3.17%
Price Target
$295.30

Amgen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
3.9% Upside
$295.30 Price Target
Short Interest
Healthy
2.08% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.80mentions of Amgen in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.75%
From $19.49 to $21.00 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.79 out of 5 stars

Medical Sector

55th out of 938 stocks

Biological Products, Except Diagnostic Industry

7th out of 154 stocks

AMGN stock logo

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Stock Price History

AMGN Stock News Headlines

7 Stocks That Will Drive the Weight Loss Drugs Market (AMGN)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Mastering Stocks in the Dow: Insights into the DJIA (AMGN)
What is the Dow Jones Industrial Average (DJIA)? The Dow Jones Industrial Average includes 30 companies, once all industrial companies. Learn more.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
4 Oversold Large Cap Stocks Yielding High Dividends
As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI,  the murmurs of potential interest rate cuts by the Federal Reserve continue, and investors find themselves at a juncture where prudence meets opportunity.
4 Oversold Large Cap Stocks Yielding High Dividends (AMGN)
Overlooked, oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation
Amazon Stock: Why it's Finally Included in the Dow Index (AMGN)
Amazon replaced Walgreens in the Dow. While a positive move for Amazon, any impact on the stock's price may be limited due to low index weighting.
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
3 Biotech Stocks to Buy on the Dip: March 2024
7 Dow Stocks to Buy on the Dip: March 2024
AMGN Mar 2024 280.000 call
Is Amgen Stock a Buy Now?
AMGN Mar 2024 267.500 call
AMGN Apr 2024 272.500 call
7 Undervalued Stocks to Buy Now
Amgen (NASDAQ:AMGN) Downgraded by StockNews.com to "Hold"
AMGN Mar 2024 282.500 call
Amgen Will Benefit From Increased Medical Spending
AMGN Apr 2024 270.000 call
AMGN Mar 2024 312.500 call
AMGN Mar 2024 282.500 put
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Ex-Dividend for 3/7 Dividend
2/15/2024
Dividend Payable
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
26,700
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$295.30
High Stock Price Target
$350.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+3.3%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
19 Analysts

Profitability

Net Income
$6.72 billion
Pretax Margin
27.86%

Debt

Sales & Book Value

Annual Sales
$28.19 billion
Cash Flow
$26.75 per share
Book Value
$11.65 per share

Miscellaneous

Free Float
533,454,000
Market Cap
$153.24 billion
Optionable
Optionable
Beta
0.58

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Amgen was last updated on Wednesday, March 27, 2024 at 11:12 PM.

Pros

Here are some ways that investors could benefit from investing in Amgen Inc.:

  • Amgen's diverse portfolio of products, including Enbrel, Prolia, and Repatha, cater to a wide range of medical conditions, providing revenue stability.
  • Continuous innovation and development of new therapeutics in areas such as oncology, inflammation, and cardiovascular diseases, ensuring future growth potential.
  • Strong collaborations with pharmaceutical companies like AstraZeneca, Novartis, and UCB for product development and commercialization, expanding market reach.
  • Positive market sentiment towards biotechnology companies, with Amgen being a key player in the biotech industry, attracting investor interest.
  • Recent stock price performance showing consistent growth, indicating a favorable investment opportunity in the company.

Cons

Investors should be bearish about investing in Amgen Inc. for these reasons:

  • Regulatory challenges and uncertainties in the biotech industry could impact product approvals and market access, leading to potential setbacks.
  • Competition from other biopharmaceutical companies in developing similar therapeutics may affect Amgen's market share and profitability.
  • Risks associated with clinical trials and drug development processes, where failures could result in financial losses and reputational damage.
  • Potential pricing pressures on Amgen's products due to healthcare reforms and cost-containment measures, affecting revenue margins.
  • Economic downturns or global health crises could impact demand for healthcare products, influencing Amgen's sales and financial performance.

AMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price target for 2024?

19 analysts have issued twelve-month price objectives for Amgen's stock. Their AMGN share price targets range from $200.00 to $350.00. On average, they anticipate the company's share price to reach $295.30 in the next year. This suggests a possible upside of 3.9% from the stock's current price.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2024?

Amgen's stock was trading at $288.02 on January 1st, 2024. Since then, AMGN shares have decreased by 1.3% and is now trading at $284.32.
View the best growth stocks for 2024 here
.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our AMGN earnings forecast
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its earnings results on Tuesday, February, 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts' consensus estimates of $4.66 by $0.05. The medical research company earned $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a trailing twelve-month return on equity of 154.27% and a net margin of 23.83%. The company's revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the company posted $4.09 earnings per share.
Read the conference call transcript
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 6th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share on Friday, June 7th. This represents a $9.00 annualized dividend and a yield of 3.17%. The ex-dividend date is Thursday, May 16th.
Read our dividend analysis for AMGN
.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 3.19%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 72.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.86% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 18.900-20.300 for the period, compared to the consensus estimate of 20.000. The company issued revenue guidance of $32.4 billion-$33.8 billion, compared to the consensus revenue estimate of $32.7 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Who are Amgen's major shareholders?

Amgen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.15%), Vanguard Group Inc. (9.16%), Primecap Management Co. CA (2.73%), Charles Schwab Investment Management Inc. (1.94%), Capital Research Global Investors (1.25%) and Price T Rowe Associates Inc. MD (1.23%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
This page (NASDAQ:AMGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners